University of Oulu

Kruis, W, Kardalinos, V, Eisenbach, T, et al. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Aliment Pharmacol Ther. 2017; 46: 282– 291.

Randomised clinical trial : mesalazine versus placebo in the prevention of diverticulitis recurrence

Saved in:
Author: Kruis, W.1; Kardalinos, V.2; Eisenbach, T.3;
Organizations: 1Cologne, Germany
2Stuhr, Germany
3Leverkusen, Germany
4Praha, Czech Republic
5Hranice, Czech Republic
6Presov, Slovakia
7Riga, Latvia
8Kaunas, Lithuania
9Nazareth, Israel
10Timisoara, Romania
11Budapest, Hungary
12Lismore, NSW, Australia
13Donetsk, Ukraine
14Bristol, CT, USA
15Hagerstown, MD, USA
16Gothenburg, Sweden
17Alcalá de Henares, Spain
18Oulu, Finland
19Callaghan, NSW, Australia
20Freiburg, Germany
21Nottingham, UK
Format: article
Version: published version
Access: open
Online Access: PDF Full Text (PDF, 0.4 MB)
Persistent link:
Language: English
Published: John Wiley & Sons, 2017
Publish Date: 2021-02-24


Background: Previous studies have reached conflicting conclusions regarding the efficacy of mesalazine in the prevention of recurrent diverticulitis.

Aim: To investigate the efficacy and safety of mesalazine granules in the prevention of recurrence of diverticulitis after acute uncomplicated diverticulitis.

Methods: Two phase 3, randomised, placebo‐controlled, double‐blind multicentre trials (SAG‐37 and SAG‐51) investigated mesalazine granules in patients with prior episodes (<6 months) of uncomplicated left‐sided diverticulitis. Patients were randomised to receive either 3 g mesalazine once daily or placebo (SAG‐37, n=345) or to receive either 1.5 g mesalazine once daily, 3 g once daily or placebo for 96 weeks (SAG‐51, n=330). The primary endpoint was the proportion of recurrence‐free patients during 48 weeks (SAG‐37 and SAG‐51) or 96 weeks (SAG‐51) of treatment.

Results: Mesalazine did not increase the proportion of recurrence‐free patients over 48 or 96 weeks compared to placebo. In SAG‐37, the proportion of recurrence‐free patients during 48 weeks was 67.9% with mesalazine and 74.4% with placebo (P=.226). In SAG‐51, the proportion of recurrence‐free patients over 48 weeks was 46.0% with 1.5 g mesalazine, 52.0% with 3 g mesalazine and 58.0% with placebo (P=.860 for 3 g mesalazine vs placebo) and over 96 weeks 6.9%, 9.8% and 23.1% respectively (P=.980 for 3 g mesalazine vs placebo). Patients with only one diverticulitis episode in the year prior to study entry had a lower recurrence risk compared to >1 episode. Safety data revealed no new adverse events.

Conclusion: Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.

see all

Series: Alimentary pharmacology and therapeutics
ISSN: 0269-2813
ISSN-E: 1365-2036
ISSN-L: 0269-2813
Volume: 46
Issue: 3
Pages: 282 - 291
DOI: 10.1111/apt.14152
Type of Publication: A1 Journal article – refereed
Field of Science: 317 Pharmacy
3121 General medicine, internal medicine and other clinical medicine
Funding: This study was funded in full by Dr. Falk Pharma GmbH. Writing support was provided by Caroline Dunstall, freelance writer, funded by Dr. Falk Pharma GmbH, and Dr. Michael Stieß, employee Dr. Falk Pharma GmbH.
Copyright information: © 2017 The Authors. Alimentary Pharmacology and Therapeutics published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.